There is a trend in pharmacy benefit plans to try to create preferred networks and narrower networks. The Centers for Medicare and Medicaid Services commissioned an analysis of relative prices at preferred pharmacies and at non-preferred ones for Part D plan sponsors who had both preferred and non-preferred networks. (CMS Analysis) CMS allows Part D sponsors to offer lower cost-sharing to beneficiaries who use preferred pharmacies, but requires that offering such lower cost-sharing must not increase payments to the plans, which presumably could only happen if drug stores paid preferred pharmacies more or the lower cost-sharing increased utilization. (As a side note, this policy of CMS’ seems counter to the CMS initiative to move to value-based purchasing. Lower drug cost-sharing has been demonstrated in several pieces of research to increase adherence and lead to lower total health spending.) Looking at pricing for the top 25 brand and top 25 generic drugs for March of 2012, the agency compared pricing for preferred and non-preferred pharmacies. CMS calculated a weighted unit cost for each category of pharmacy network. For the majority of sponsors, the aggregate weighted unit costs were lower in the preferred networks, with a range of savings from less than 1% to over 24%. In 4 of 13 plans, however, these aggregate unit costs were higher for the preferred networks, ranging from 2% to 11% more. The plans with higher costs in the preferred network covered about 11% of total stand-alone Part D beneficiaries, but since more preferred networks are being offered, CMS is concerned this number might grow. CMS ended the analysis by saying it intended to consider options for rulemaking to ensure that higher prices aren’t resulting from the use of preferred networks.
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
It may be investors that need the redesign. They just keep pouring money into this digital health crap despite all the losses. Redesign Health claims that it makes money by...
September 16, 2022
In truth, this seems like more money down a rathole. Google’s parent and other investors are putting a billion dollars into Google’s health arm, Verily. Apparently want to compete with...
September 12, 2022
It is like investors have learned nothing from the past two years. Even supposedly smart investors like Morgan Health, which is making a $20 million contribution to LetsGetChecked, which supposedly...
September 12, 2022
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace